IPIC Message Board - Msg: 3310085

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WeirdPro Randy who wrote (1001)	1/31/1998 1:20:00 PM
From: NeuroInvestment	Read Replies (1) of 1359

Given that there has been a complete absence of bad news regarding valvular pathology for many weeks, the fact is that the discussions were fairly intensive when all negative reports were already on the table and available for due diligence inspection. Thus I believe the likelihood is that the deal fell apart for other reasons. One cautionary note is that the 1000 patient study on Redux II (once-daily formulation) is wrapping up; that will give echocardiogram data on patients who were exposed to Redux for 2-4 months (blinded, with placebo control). If that data were negative and known to AHP/SKB, that would be pertinent, but I do not believe that is the case. The rumors I have heard about the study have thus far been along the line of an absence of valvular pathology in Redux II users. And the limited duration of usage would argue against significant pathology (given my present operative hypothesis that risk, if any, would be correlated with duration of use) But those are just rumors, and cannot be given much credence. Hopefully sometime in February there will be an unblinding of the data and some type of public release. NeuroInvestment (www.neuroinv.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next